A living, evidence-informed guideline published in the Journal of the American Dental Association assessed commercially available salivary adjunct tests for the early detection of oral squamous cell carcinoma and potentially malignant disorders, using a living systematic review and GRADE evidence-to-decision methods.
The panel made two research-only recommendations: salivary tests should not be used outside research, either to screen adults without mucosal abnormalities or to decide whether a visible abnormality needs biopsy. It added three good practice statements: examine the mouth of every adult, and biopsy or refer any persistent mucosal abnormality.
The tests reviewed are those marketed in the United States, but the message travels. In India, where oral cancer is among the commonest cancers in men and tobacco and areca nut use are widespread, the cheapest and best-supported detection tool remains a careful look and a feel inside the mouth during routine consultations. A normal saliva test should never delay biopsy of a persisting lesion.
- Make an oral examination part of routine adult consultations, particularly for tobacco and areca nut users.
- Do not use a salivary test to decide whether a lesion needs biopsy.
- Refer persistent mucosal abnormalities for biopsy; it remains the reference standard.
- Do not offer salivary tests as population screening outside research.
Why it matters
Commercial tests could falsely reassure, delaying the biopsy that makes the diagnosis.
Don't overread it
The guideline does not say salivary tests can never work — only that current evidence does not support using them in practice.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for family medicine, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free